Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases

被引：56

作者：

Lierman, E. ^{[1
,3
]}

Smits, S. ^{[1
]}

Cools, J. ^{[1
,2
]}

Dewaele, B. ^{[3
]}

Debiec-Rychter, M. ^{[1
,3
]}

Vandenberghe, P. ^{[1
,3
]}

机构：

[1] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium

[2] CME VIB11, Dept Mol & Dev Genet, Louvain, Belgium

[3] Univ Hosp Leuven, Ctr Human Genet, Louvain, Belgium

来源：

LEUKEMIA | 2012年 / 26卷 / 07期

关键词：

GASTROINTESTINAL STROMAL TUMOR; BCR-ABL INHIBITOR; EOSINOPHILIC LEUKEMIA; MYELOID-LEUKEMIA; IN-VITRO; SORAFENIB; MUTATION; AP24534; ABNORMALITIES; PATIENT;

D O I：

10.1038/leu.2012.8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1693 / 1695

页数：3

共 15 条

[1] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[2] Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders [J].

Cross, Nicholas C. P. ;

Reiter, Andreas .

ACTA HAEMATOLOGICA, 2008, 119 (04) :199-206

[3] KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours [J].

Debiec-Rychter, Maria ;

Sciot, Raf ;

Le Cesne, Axel ;

Schlemmer, Marcus ;

Hohenberger, Peter ;

van Oosterom, Allan T. ;

Blay, Jean-Yves ;

Leyvraz, Serge ;

Stul, Michel ;

Casali, Paolo G. ;

Zalcberg, John ;

Verweij, Jaap ;

Van Glabbeke, Martine ;

Hagemeijer, Anne ;

Judson, Ian .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1093-1103

[4] Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias [J].

Gotlib, J. ;

Cools, J. .

LEUKEMIA, 2008, 22 (11) :1999-2010

[5] Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies [J].

Gozgit, Joseph M. ;

Wong, Matthew J. ;

Wardwell, Scott ;

Tyner, Jeffrey W. ;

Loriaux, Marc M. ;

Mohemmad, Qurish K. ;

Narasimhan, Narayana I. ;

Shakespeare, William C. ;

Wang, Frank ;

Druker, Brian J. ;

Clackson, Tim ;

Rivera, Victor M. .

MOLECULAR CANCER THERAPEUTICS, 2011, 10 (06) :1028-1035

[6] Sorafenib inhibits the imatinib-resistant KITT6701 gatekeeper mutation in gastrointestinal stromal tumor [J].

Guo, Tianhua ;

Agaram, Narasimhan P. ;

Wong, Grace C. ;

Hom, Glory ;

D'Adamo, David ;

Maki, Robert G. ;

Schwartz, Gary K. ;

Veach, Darren ;

Clarkson, Bayard D. ;

Singer, Samuel ;

DeMatteo, Ronald P. ;

Besmer, Peter ;

Antonescu, Cristina R. .

CLINICAL CANCER RESEARCH, 2007, 13 (16) :4874-4881

[7] FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib [J].

Lierman, E. ;

Michaux, L. ;

Beullens, E. ;

Pierre, P. ;

Marynen, P. ;

Cools, J. ;

Vandenberghe, P. .

LEUKEMIA, 2009, 23 (05) :845-851

[8] Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation [J].

Metzgeroth, G. ;

Erben, P. ;

Martin, H. ;

Mousset, S. ;

Teichmann, M. ;

Walz, C. ;

Klippstein, T. ;

Hochhaus, A. ;

Cross, N. C. P. ;

Hofmann, W-K ;

Reiter, A. .

LEUKEMIA, 2012, 26 (01) :162-164

[9] AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance [J].

O'Hare, Thomas ;

Shakespeare, William C. ;

Zhu, Xiaotian ;

Eide, Christopher A. ;

Rivera, Victor M. ;

Wang, Frank ;

Adrian, Lauren T. ;

Zhou, Tianjun ;

Huang, Wei-Sheng ;

Xu, Qihong ;

Metcalf, Chester A., III ;

Tyner, Jeffrey W. ;

Loriaux, Marc M. ;

Corbin, Amie S. ;

Wardwell, Scott ;

Ning, Yaoyu ;

Keats, Jeffrey A. ;

Wang, Yihan ;

Sundaramoorthi, Raji ;

Thomas, Mathew ;

Zhou, Dong ;

Snodgrass, Joseph ;

Commodore, Lois ;

Sawyer, Tomi K. ;

Dalgarno, David C. ;

Deininger, Michael W. N. ;

Druker, Brian J. ;

Clackson, Tim .

CANCER CELL, 2009, 16 (05) :401-412

[10] Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate [J].

Prenen, H ;

Cools, J ;

Mentens, N ;

Folens, C ;

Sciot, R ;

Schöffski, P ;

Van Oosterom, A ;

Marynen, P ;

Debiec-Rychter, M .

CLINICAL CANCER RESEARCH, 2006, 12 (08) :2622-2627

← 1 2 →